139 related articles for article (PubMed ID: 1661978)
1. Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection.
Erturk M; Phillpotts RJ; Welch MJ; Jennings R
Vaccine; 1991 Oct; 9(10):728-34. PubMed ID: 1661978
[TBL] [Abstract][Full Text] [Related]
2. Protection and serum antibody responses in guinea-pigs and mice immunized with HSV-1 antigen preparations obtained using different detergents.
Ertürk M; Welch MJ; Phillpotts RJ; Jennings R
Vaccine; 1989 Oct; 7(5):431-6. PubMed ID: 2554607
[TBL] [Abstract][Full Text] [Related]
3. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
[TBL] [Abstract][Full Text] [Related]
4. Vaccine induced HSV 1 antibodies fail to correlate with protection against HSV 2 in guinea pigs.
Welch MJ; Ridgeway PH; Phillpotts RJ
FEMS Microbiol Immunol; 1988 Dec; 1(3):157-62. PubMed ID: 2856207
[TBL] [Abstract][Full Text] [Related]
5. Effects of DNA immunization formulated with bupivacaine in murine and guinea pig models of genital herpes simplex virus infection.
Bernstein DI; Tepe ER; Mester JC; Arnold RL; Stanberry LR; Higgins T
Vaccine; 1999 Apr; 17(15-16):1964-9. PubMed ID: 10217595
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.
Stanberry LR; Bernstein DI; Burke RL; Pachl C; Myers MG
J Infect Dis; 1987 May; 155(5):914-20. PubMed ID: 3031173
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, protective efficacy, and non-replicative status of the HSV-2 vaccine candidate HSV529 in mice and guinea pigs.
Bernard MC; Barban V; Pradezynski F; de Montfort A; Ryall R; Caillet C; Londono-Hayes P
PLoS One; 2015; 10(4):e0121518. PubMed ID: 25837802
[TBL] [Abstract][Full Text] [Related]
8. Herpes simplex virus genital infection of the female guinea pig as a model for the evaluation of an experimental vaccine.
Thornton B; Baskerville A; Bailey NE; Melling JM; Hambleton P
Vaccine; 1984 Jun; 2(2):141-8. PubMed ID: 6099646
[TBL] [Abstract][Full Text] [Related]
9. A test for the relative potency of herpes simplex virus vaccines based upon the female guinea-pig model of HSV 2 genital infection.
Phillpotts RJ; Welch MJ; Ridgeway PH; Walkland AC; Melling J
J Biol Stand; 1988 Apr; 16(2):109-18. PubMed ID: 2836425
[TBL] [Abstract][Full Text] [Related]
10. Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.
Mohamedi SA; Brewer JM; Alexander J; Heath AW; Jennings R
Vaccine; 2000 Apr; 18(20):2083-94. PubMed ID: 10715522
[TBL] [Abstract][Full Text] [Related]
11. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs.
Simms JR; Heath AW; Jennings R
J Infect Dis; 2000 Apr; 181(4):1240-8. PubMed ID: 10762560
[TBL] [Abstract][Full Text] [Related]
12. Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C.
Mester JC; Twomey TA; Tepe ET; Bernstein DI
Vaccine; 1999 Dec; 18(9-10):875-83. PubMed ID: 10580201
[TBL] [Abstract][Full Text] [Related]
13. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D.
Berman PW; Gregory T; Crase D; Lasky LA
Science; 1985 Mar; 227(4693):1490-2. PubMed ID: 2983428
[TBL] [Abstract][Full Text] [Related]
14. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
Aurelian L; Smith CC; Wachsman M; Paoletti E
Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
[TBL] [Abstract][Full Text] [Related]
15. Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.
Awasthi S; Balliet JW; Flynn JA; Lubinski JM; Shaw CE; DiStefano DJ; Cai M; Brown M; Smith JF; Kowalski R; Swoyer R; Galli J; Copeland V; Rios S; Davidson RC; Salnikova M; Kingsley S; Bryan J; Casimiro DR; Friedman HM
J Virol; 2014 Feb; 88(4):2000-10. PubMed ID: 24284325
[TBL] [Abstract][Full Text] [Related]
16. Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease.
Da Costa XJ; Bourne N; Stanberry LR; Knipe DM
Virology; 1997 May; 232(1):1-12. PubMed ID: 9185583
[TBL] [Abstract][Full Text] [Related]
17. Antibody response to herpes simplex virus glycoprotein D: effects of acyclovir and relation to recurrence.
Bernstein DI; Stanberry LR; Harrison CJ; Shukla R; Kappes JC; Myers MG
J Infect Dis; 1987 Sep; 156(3):423-9. PubMed ID: 3039009
[TBL] [Abstract][Full Text] [Related]
18. Systemic and mucosal cell mediated immune responses against herpes simplex virus in vaccinated guinea-pigs detected by lymphocyte proliferation and monoclonal antibodies against macrophages and T cells.
McBride BW; Ridgeway P; Phillpotts R; Newell DG
Vaccine; 1989 Oct; 7(5):409-16. PubMed ID: 2554606
[TBL] [Abstract][Full Text] [Related]
19. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
[TBL] [Abstract][Full Text] [Related]
20. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models.
Mishkin EM; Fahey JR; Kino Y; Klein RJ; Abramovitz AS; Mento SJ
Vaccine; 1991 Mar; 9(3):147-53. PubMed ID: 1645898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
